These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10203236)

  • 1. Quinolinic acid lesion of the nigrostriatal pathway: effect on turning behaviour and protection by elevation of endogenous kynurenic acid in Rattus norvegicus.
    Miranda AF; Sutton MA; Beninger RJ; Jhamandas K; Boegman RJ
    Neurosci Lett; 1999 Mar; 262(2):81-4. PubMed ID: 10203236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid.
    Miranda AF; Boegman RJ; Beninger RJ; Jhamandas K
    Neuroscience; 1997 Jun; 78(4):967-75. PubMed ID: 9174065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
    Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
    Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities.
    Carpenedo R; Chiarugi A; Russi P; Lombardi G; Carlà V; Pellicciari R; Mattoli L; Moroni F
    Neuroscience; 1994 Jul; 61(2):237-43. PubMed ID: 7969905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase.
    Chiarugi A; Carpenedo R; Molina MT; Mattoli L; Pellicciari R; Moroni F
    J Neurochem; 1995 Sep; 65(3):1176-83. PubMed ID: 7643095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons.
    Erhardt S; Oberg H; Mathé JM; Engberg G
    Amino Acids; 2001; 20(4):353-62. PubMed ID: 11452979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of quinolinic and kynurenic acid content in the rat brain: effects of endotoxins and nicotinylalanine.
    Moroni F; Russi P; Gallo-Mezo MA; Moneti G; Pellicciari R
    J Neurochem; 1991 Nov; 57(5):1630-5. PubMed ID: 1833509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in organotypic hippocampal slice cultures.
    Carpenedo R; Meli E; Peruginelli F; Pellegrini-Giampietro DE; Moroni F
    J Neurochem; 2002 Sep; 82(6):1465-71. PubMed ID: 12354294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
    Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
    J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kynurenine 3-hydroxylase inhibition in rats: effects on extracellular kynurenic acid concentration and N-methyl-D-aspartate-induced depolarisation in the striatum.
    Urenjak J; Obrenovitch TP
    J Neurochem; 2000 Dec; 75(6):2427-33. PubMed ID: 11080194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase.
    Pellicciari R; Natalini B; Costantino G; Mahmoud MR; Mattoli L; Sadeghpour BM; Moroni F; Chiarugi A; Carpenedo R
    J Med Chem; 1994 Mar; 37(5):647-55. PubMed ID: 8126705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of peripheral loading with kynurenine and probenecid on extracellular striatal kynurenic acid concentrations.
    Miller JM; MacGarvey U; Beal MF
    Neurosci Lett; 1992 Oct; 146(1):115-8. PubMed ID: 1475044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute and chronic changes in kynurenate formation following an intrastriatal quinolinate injection in rats.
    Ceresoli-Borroni G; Guidetti P; Schwarcz R
    J Neural Transm (Vienna); 1999; 106(3-4):229-42. PubMed ID: 10392532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excitotoxic injury stimulates pro-drug-induced 7-chlorokynurenate formation in the rat striatum in vivo.
    Lee SC; Schwarcz R
    Neurosci Lett; 2001 May; 304(3):185-8. PubMed ID: 11343833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kynurenergic manipulations influence excitatory synaptic function and excitotoxic vulnerability in the rat hippocampus in vivo.
    Wu HQ; Guidetti P; Goodman JH; Varasi M; Ceresoli-Borroni G; Speciale C; Scharfman HE; Schwarcz R
    Neuroscience; 2000; 97(2):243-51. PubMed ID: 10799756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologically elevated levels of endogenous kynurenic acid prevent nicotine-induced activation of nigral dopamine neurons.
    Erhardt S; Oberg H; Engberg G
    Naunyn Schmiedebergs Arch Pharmacol; 2001 Jan; 363(1):21-7. PubMed ID: 11191832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kynurenic acid-enhancing and anti-ischemic effects of the potent kynurenine 3-hydroxylase inhibitor FCE 28833 in rodents.
    Speciale C; Cini M; Wu HQ; Salvati P; Schwarcz R; Molinari A; Calabresi M; Varasi M
    Adv Exp Med Biol; 1996; 398():221-7. PubMed ID: 8906269
    [No Abstract]   [Full Text] [Related]  

  • 18. In situ produced 7-chlorokynurenate provides protection against quinolinate- and malonate-induced neurotoxicity in the rat striatum.
    Guidetti P; Wu HQ; Schwarcz R
    Exp Neurol; 2000 May; 163(1):123-30. PubMed ID: 10785450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase.
    Chiarugi A; Carpenedo R; Moroni F
    J Neurochem; 1996 Aug; 67(2):692-8. PubMed ID: 8764597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.